MCID: INT070
MIFTS: 58

Intestinal Obstruction

Categories: Fetal diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Intestinal Obstruction

Summaries for Intestinal Obstruction

MedlinePlus: 41 An intestinal obstruction occurs when food or stool cannot move through the intestines. The obstruction can be complete or partial. There are many causes. The most common are adhesions, hernias, cancers, and certain medicines. Symptoms include: Severe abdominal pain or cramping Vomiting Bloating Loud bowel sounds Swelling of the abdomen Inability to pass gas Constipation A complete intestinal obstruction is a medical emergency. It often requires surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Intestinal Obstruction, also known as inspissated milk syndrome, is related to hirschsprung disease 1 and ileus, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Intestinal Obstruction is SLC26A3 (Solute Carrier Family 26 Member 3), and among its related pathways/superpathways are Signal Transduction and Cytoskeletal Signaling. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, small intestine and colon, and related phenotypes are no effect and no effect

Related Diseases for Intestinal Obstruction

Diseases in the Intestinal Obstruction family:

Intestinal Pseudo-Obstruction

Diseases related to Intestinal Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 913)
# Related Disease Score Top Affiliating Genes
1 hirschsprung disease 1 32.2 RET NRTN GDNF EDNRB EDN3 ACTG2
2 ileus 32.0 GUCY2C CRP CFTR
3 intestinal pseudo-obstruction 31.8 SGO1 RET FLNA EDNRB EDN3 CFTR
4 rectal benign neoplasm 31.1 KRT7 KRT20 CDX2
5 lymphangioma 31.0 KRT7 KRT20 CDX2 CD8A
6 constipation 31.0 RET NRTN GUCY2C GDNF FLNA EDNRB
7 colonic benign neoplasm 31.0 KRT7 KRT20 CDX2 CD8A
8 intestinal tuberculosis 30.9 NOD2 CRP
9 intestinal perforation 30.9 NOD2 KRT7 CRP CD8A
10 megacolon 30.8 RET NRTN GDNF EDNRB EDN3
11 pseudomyxoma peritonei 30.8 KRT7 KRT20 CDX2
12 diarrhea 30.7 SLC26A3 NOD2 MVK GUCY2C CFTR
13 megacystis-microcolon-intestinal hypoperistalsis syndrome 1 30.7 SGO1 FLNA ACTG2
14 familial mediterranean fever 30.7 NOD2 MVK CRP
15 small intestine cancer 30.7 KRT7 KRT20 CDX2
16 appendix adenocarcinoma 30.6 KRT7 KRT20 CDX2
17 cystic teratoma 30.6 KRT7 KRT20 CDX2
18 neuroendocrine tumor 30.6 RET MTOR KRT20 CDX2
19 enterocolitis 30.4 NOD2 CRP
20 hemorrhoid 30.4 KRT7 KRT20 CRP
21 small intestine adenocarcinoma 30.4 KRT7 CDX2
22 adenoma 30.4 SLC26A3 RET KRT7 KRT20 CDX2
23 exanthem 30.3 MTOR CRP CD8A
24 cholangiocarcinoma 30.3 MTOR KRT7 KRT20 CDX2
25 hydronephrosis 30.3 KRT7 CRP ACTG2
26 jejunal adenocarcinoma 30.3 KRT7 CDX2
27 sigmoid neoplasm 30.3 KRT7 KRT20 CDX2
28 signet ring cell adenocarcinoma 30.3 KRT7 KRT20 CDX2
29 mucinous adenocarcinoma 30.3 KRT7 KRT20 CDX2
30 ascending colon cancer 30.2 KRT7 CDX2
31 ampulla of vater adenocarcinoma 30.2 KRT7 KRT20 CDX2
32 mucinous cystadenocarcinoma 30.2 KRT7 KRT20 CDX2
33 benign teratoma 30.2 KRT7 KRT20 CDX2
34 behcet syndrome 30.2 NOD2 MVK CRP CD8A
35 cystic kidney disease 30.2 MTOR EDNRB CRP CFTR
36 cystitis 30.2 KRT7 KRT20 CRP
37 pheochromocytoma 30.2 RET KRT7 GDNF EDN3 CRP
38 abdominal tuberculosis 30.2 NOD2 CRP CD8A
39 periodic fever, familial, autosomal dominant 30.1 NOD2 MVK CRP
40 cholangitis 30.1 NOD2 CRP CFTR
41 vesicoureteral reflux 30.0 RET GDNF CRP
42 meconium ileus 11.7
43 volvulus of midgut 11.3
44 paralytic ileus 11.2
45 peritonitis 11.2
46 colonic atresia 11.2
47 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.2
48 ascaris lumbricoides infection 11.2
49 crohn's disease 11.2
50 omphalomesenteric cyst 11.2

Comorbidity relations with Intestinal Obstruction via Phenotypic Disease Network (PDN): (show top 50) (show all 57)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Anxiety
Ascending Colon Cancer Bronchitis
Candidiasis Cecal Benign Neoplasm
Cervical Cancer Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease Chylomicron Retention Disease
Colorectal Cancer Crohn's Disease
Decubitus Ulcer Deficiency Anemia
Descending Colon Cancer Enterovesical Fistula
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Gastric Cancer
Gastrointestinal System Cancer Generalized Atherosclerosis
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Hypertension, Essential
Hypothyroidism Inflammatory Bowel Disease 1
Intestinal Disease Intestinal Perforation
Iron Deficiency Anemia Irritable Bowel Syndrome
Jejunal Cancer Kidney Disease
Marasmus Neutropenia
Osteoporosis Ovarian Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Peritonitis
Postgastrectomy Syndrome Protein-Energy Malnutrition
Radiation Cystitis Rectosigmoid Junction Neoplasm

Graphical network of the top 20 diseases related to Intestinal Obstruction:



Diseases related to Intestinal Obstruction

Symptoms & Phenotypes for Intestinal Obstruction

UMLS symptoms related to Intestinal Obstruction:


abdominal pain; constipation; diarrhea; dyspepsia; heartburn; icterus; nausea and vomiting; gastrointestinal gas

GenomeRNAi Phenotypes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ACTG2 CD8A CDX2 CFTR CRP EDN3
2 no effect GR00402-S-2 10.17 ACTG2 CDX2 CFTR CRP EDN3 EDNRB

MGI Mouse Phenotypes related to Intestinal Obstruction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ACTG2 CDX2 CFTR CRP EDNRB FLNA
2 endocrine/exocrine gland MP:0005379 10.03 CD8A CDX2 CFTR EDNRB GDNF MTOR
3 digestive/alimentary MP:0005381 9.93 CDX2 CFTR EDN3 EDNRB FLNA GDNF
4 cellular MP:0005384 9.77 CD8A CDX2 CFTR EDNRB FLNA GDNF
5 mortality/aging MP:0010768 9.5 CD8A CDX2 CFTR EDN3 EDNRB FLNA

Drugs & Therapeutics for Intestinal Obstruction

Drugs for Intestinal Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
3
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
6
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
7
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
10
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
11 Analgesics, Non-Narcotic Phase 4
12 Adrenergic alpha-Agonists Phase 4
13 Adrenergic Agonists Phase 4
14 Adrenergic Agents Phase 4
15 Anesthetics, Intravenous Phase 4
16 Anesthetics, General Phase 4
17 Hypnotics and Sedatives Phase 4
18 Excitatory Amino Acid Antagonists Phase 4
19 Anesthetics, Dissociative Phase 4
20 Neuromuscular Nondepolarizing Agents Phase 4
21 Neuromuscular Blocking Agents Phase 4
22 Anti-Inflammatory Agents Phase 4
23 Anesthetics Phase 4
24 Narcotics Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Analgesics Phase 4
27 Anesthetics, Local Phase 4
28 Analgesics, Opioid Phase 4
29
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
30
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
31
Clavulanic acid Approved, Vet_approved Phase 3 58001-44-8 5280980
32
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
33
Cefuroxime Approved Phase 3 55268-75-2 5479529
34
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
35
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
36
Phenobarbital Approved, Investigational Phase 3 50-06-6 4763
37 Narcotic Antagonists Phase 3
38 Neurotransmitter Agents Phase 3
39 Cytochrome P-450 Enzyme Inhibitors Phase 3
40 Antifungal Agents Phase 3
41
Cefuroxime axetil Phase 3 3379942
42 beta-Lactamase Inhibitors Phase 3
43 GABA Modulators Phase 3
44 Anticonvulsants Phase 3
45
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
46
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
47
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
48
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
49
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
50
Fluorouracil Approved Phase 2 51-21-8 3385

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Ketofol vs Dexmedetomidine for Preventing Post-operative Delirium in Elderly Patients Undergoing Intestinal Obstruction Surgeries. A Randomized Controlled Study Completed NCT04816162 Phase 4 ketofol;dexmedetomidine
2 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Completed NCT01507246 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
3 Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction Completed NCT00389116 Phase 4 gastrograffin;water
4 Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction Completed NCT01082627 Phase 4 Somatostatin
5 Gastrografin Use in Small Bowel Obstruction Caused by Adherences Completed NCT00601809 Phase 4 Gastrografin®: G
6 Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery Completed NCT00531739 Phase 4
7 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
8 The Effects of Preoperative High-dose Dexamethasone on Inflammatory Response and Recovery After Emergency Laparotomy, a Randomized, Double-blind, Placebo-controlled Clinical Trial - AHA STEROID TRIAL Recruiting NCT04791566 Phase 4 Dexamethasone 1 mg/kg;Physiologic saline
9 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507233 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
10 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507220 Phase 4 morphine sulfate;bupivacaine liposome extended-release injectable suspension
11 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy) Terminated NCT02058290 Phase 4 IV morphine sulfate or Sponsor-approved equivalent;EXPAREL
12 The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients. Withdrawn NCT03334578 Phase 4 Gastrografin
13 Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer. Unknown status NCT02198898 Phase 3
14 A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-malignant Pain or Malignant Pain Unknown status NCT00020605 Phase 3 naloxone hydrochloride
15 Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial Unknown status NCT00164879 Phase 3
16 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
17 Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial. Completed NCT00758186 Phase 3
18 Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting Completed NCT01834430 Phase 3
19 Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis Completed NCT01524081 Phase 3 Metronidazole, Cefuroxime;Amoxicillin (+ clavulanic acid) and Fluconazole;Placebo
20 Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial Completed NCT00529412 Phase 3
21 Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery Completed NCT00140868 Phase 3
22 The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study Recruiting NCT03573921 Phase 2, Phase 3 Gastrografin
23 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Withdrawn NCT01473290 Phase 3
24 Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Completed NCT01076803 Phase 2 Lanreotide (acetate)
25 Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed NCT00332696 Phase 2 Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
26 An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction Completed NCT02275338 Phase 2 Lanreotide Autogel
27 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
28 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
29 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
30 A Phase II, Non-Randomized, Multi-Cohort Trial of Docetaxel, Oxaliplatin and 5-Fluorouracil in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis and Inoperable Malignant Bowel Obstruction Recruiting NCT04840264 Phase 2 Docetaxel;Oxaliplatin;5Fluorouracil
31 A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY) Terminated NCT02365584 Phase 2 lanreotide (Autogel formulation)
32 Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center Terminated NCT04027348 Phase 2 Dexamethasone;Metoclopramide;Octreotide
33 Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction Terminated NCT01083537 Phase 1, Phase 2 Cisplatin;Paclitaxel
34 Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction Terminated NCT02692638 Phase 2
35 Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects. Completed NCT01596764 Phase 1 Loperamide placebo;Loperamide;Sulfasalazine;Placebo of MNTX and NLX;Naloxone;Methylnaltrexone
36 Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects Completed NCT01596777 Phase 1 Loperamide;Loperamide placebo;Methylnaltrexone placebo;Methylnaltrexone 12 mg sc.;Methylnaltrexone IR capsule;Methylnaltrexone ER capsule;Sulfasalazine
37 Therapeutic Oxygen for Gastrointestinal Atony (TOGA): Pilot Trial - Management of Acute Colonic Pseudo-Obstruction With Oxygen Supplementation Completed NCT03386136 Phase 1 100% Oxygen
38 Hypertonic Saline 3% Compared to Hypertonic Saline 1.8% for Fluid Management of Intestinal Obstruction Surgery Unknown status NCT03741257 Hypertonic saline
39 Prospective Multicenter Validation of a Clinicoradiological Score for Predicting the Severity of Strangulated Small Bowel Occlusion Unknown status NCT01125280
40 Ostomy in Continuity or Conventional Ileostomy for Complex Pediatric Intestinal Diseases: a Retrospective Multicentric Analysis Unknown status NCT04213976
41 Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients Unknown status NCT01669044 dexmedetomidine;propofol
42 Evaluation of RightBio Metrics', RightSpot pH Indicator, for Rapid Bedside Verification of Proper Nasogastric/ Orogastric Tube Placement in Emergency Department & Intensive Care Unit Patients Unknown status NCT01561729
43 Diagnostic Scoring for Small Bowel Obstruction Unknown status NCT03461744
44 The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO Unknown status NCT02639195
45 Nasogastric Tube Clamping Trial: Is it Useful? A Proposed Algorithm for Removal. Unknown status NCT04001985
46 Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction: a Multicentre, Prospective, Open Label, Cohort Study Unknown status NCT01997684
47 The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction:A Retrospective Study Unknown status NCT03642288 Gastrografin
48 Laparoscopic Versus Open Adhesiolysis for Small Bowel Obstruction - A Multicenter, Prospective, Randomized, Controlled Trial Unknown status NCT01867528
49 Prospective Nationwide Audit of the Management of Adhesive Small Bowel Obstruction: a Snapshot Study Unknown status NCT03786159
50 Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation Unknown status NCT01934283

Search NIH Clinical Center for Intestinal Obstruction

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Heavy mineral oil
Mineral Oil
Mineral Oil, Light
MINERAL OIL,EXTRA HEAVY
MINERAL OIL,MEDIUM
MINERAL OIL,REFINED

Cochrane evidence based reviews: intestinal obstruction

Genetic Tests for Intestinal Obstruction

Genetic tests related to Intestinal Obstruction:

# Genetic test Affiliating Genes
1 Intestinal Obstruction 28

Anatomical Context for Intestinal Obstruction

Organs/tissues related to Intestinal Obstruction:

MalaCards : Kidney, Small Intestine, Colon, Pancreas, Appendix, Lymph Node, Liver

Publications for Intestinal Obstruction

Articles related to Intestinal Obstruction:

(show top 50) (show all 12579)
# Title Authors PMID Year
1
Clinical efficacy of acupuncture in patients with adhesive intestinal obstruction: A meta-analysis. 62 41
36221368 2022
2
Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction. 5
29781137 2018
3
Familial visceral myopathy diagnosed by exome sequencing of a patient with chronic intestinal pseudo-obstruction. 5
24777424 2014
4
Segregation of a missense variant in enteric smooth muscle actin γ-2 with autosomal dominant familial visceral myopathy. 5
22960657 2012
5
Update on SLC26A3 mutations in congenital chloride diarrhea. 5
21394828 2011
6
Postoperative hyperlipasemia in perforated appendicitis in children. 41
36217785 2022
7
Diagnostic value of the microcolon using ultrasonography in small bowel atresia. 41
36203132 2022
8
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. 53 62
18782827 2008
9
Impact of nutrition on phenotype in CFTR-deficient mice. 53 62
17805210 2007
10
Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. 53 62
17030173 2006
11
Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. 53 62
16418321 2006
12
Distal intestinal obstruction syndrome in adults with cystic fibrosis. 53 62
15181619 2004
13
Liver cirrhosis and portal hypertension in cystic fibrosis. 53 62
14501614 2003
14
Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice. 53 62
11774071 2002
15
Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. 53 62
10959824 2000
16
[Gastrointestinal complications of adult patients with cystic fibrosis]. 53 62
10494610 1999
17
Clinical and genetic risk factors for cystic fibrosis-related liver disease. 53 62
9917439 1999
18
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. 53 62
8589719 1996
19
Costs Associated With Surgical Infections at a Tertiary Referral Hospital in Rwanda. 62
35964487 2022
20
Hyperglycaemia and the risk of post-surgical adhesion. 62
32536284 2022
21
Prevention of peritoneal adhesions formation by core-shell electrospun ibuprofen-loaded PEG/silk fibrous membrane. 62
35296208 2022
22
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. 62
35304622 2022
23
Mechanical intestinal obstruction in underweight, elderly women due to an incarcerated obturator hernia. 62
36086938 2022
24
Acute intestinal obstruction caused by paraduodenal hernia. 62
35866494 2022
25
Loss of NKCC1 function increases epithelial tight junction permeability by upregulating claudin-2 expression. 62
35968893 2022
26
Preliminary study of CT features of intermediate- and high-grade alimentary lymphoma and adenocarcinoma in cats. 62
34663124 2022
27
Collateral damage of wandering ProTacks. 62
36257517 2022
28
An atypical case of intestinal obstruction. 62
36272730 2022
29
Iatrogenic Small Intestinal Obstruction. 62
36263808 2022
30
A 10 cm pedunculated duodenal Brunner gland hamartoma, case report and literature review. 62
36270207 2022
31
Congenital pouch colon: Case report and literature review. 62
36268354 2022
32
Surgical considerations in cystic fibrosis: what every general surgeon needs to know. 62
35920692 2022
33
Pleiotropic modifiers of age-related diabetes and neonatal intestinal obstruction in cystic fibrosis. 62
36206743 2022
34
Early Bleeding After Laparoscopic Roux-en-Y Gastric Bypass: Incidence, Risk Factors, and Management - a 21-Year Experience. 62
35932414 2022
35
Demographics and medical comorbidities among hospitalized patients with Prader-Willi Syndrome: A National Inpatient Sample analysis. 62
35838073 2022
36
Meconium Ileus, Distal Intestinal Obstruction Syndrome, and Other Gastrointestinal Pathology in the Cystic Fibrosis Patient. 62
36209752 2022
37
Caecal bascule - A variant of caecal volvulus: Review of diagnostic challenges and approaches. 62
34789426 2022
38
ABCL-310 Triple Metachronous Malignancies in Primary Diagnosed Diffuse Large B-Cell Lymphoma Patient: A Case Report. 62
36164075 2022
39
Ischemic enteritis resulting from polycythemia vera. 62
35831680 2022
40
Redo Gastric Bypass following internal herniation with gangrenous roux limb, in second trimester pregnancy: How safe? 62
36270206 2022
41
Abdominal cocoon syndrome: An extremely rare cause of intestinal obstruction. 62
35450764 2022
42
Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: 5-Year Outcomes of the KLASS-02 Randomized Clinical Trial. 62
35857305 2022
43
Laparoscopic Splenectomy of a Wandering Pelvic Splenomegaly in a Young Woman Treated in Childhood with Surgery for Diaphragmatic Hernia and Adhesiolysis for Intestinal Obstruction. 62
36184835 2022
44
Hirschsprung-Associated Enterocolitis: Transformative Research from Bench to Bedside. 62
35649434 2022
45
A rare presentation of Morgagni hernia in an adult with strangulated ileum: A case report. 62
36156457 2022
46
Acute abdominal pain due to sigmoid volvulus with persistent descending mesocolon: a case report. 62
36180925 2022
47
Sigmoid lipoma as an exceptional cause of intussusception and bowel obstruction in adults: A case report and review of literature. 62
36032208 2022
48
Adult intussusception due to ileal polyp - A case report. 62
36096079 2022
49
Mechanical ileus of the small bowel due to an inflamed Meckel's diverticulum with an enterolith - a case report with literature review. 62
36259265 2022
50
Clinical profile and management of perforation peritonitis in Bharatpur hospital, Nepal: A prospective study. 62
36268443 2022

Variations for Intestinal Obstruction

ClinVar genetic disease variations for Intestinal Obstruction:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SLC26A3 NM_000111.3(SLC26A3):c.1000G>T (p.Glu334Ter) SNV Pathogenic
978618 rs1208952914 GRCh37: 7:107423769-107423769
GRCh38: 7:107783324-107783324
2 SLC26A3 NM_000111.3(SLC26A3):c.269_270dup (p.Gly91fs) DUP Pathogenic
55994 rs386833476 GRCh37: 7:107434187-107434188
GRCh38: 7:107793742-107793743
3 ACTG2 NM_001615.4(ACTG2):c.442C>T (p.Arg148Cys) SNV Likely Pathogenic
1177291 GRCh37: 2:74136257-74136257
GRCh38: 2:73909130-73909130
4 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter) SNV Uncertain Significance
599007 rs764412749 GRCh37: 19:42752628-42752628
GRCh38: 19:42248476-42248476
5 GATA4 NM_001308093.3(GATA4):c.94G>C (p.Ala32Pro) SNV Uncertain Significance
599008 rs773545065 GRCh37: 8:11565915-11565915
GRCh38: 8:11708406-11708406

Expression for Intestinal Obstruction

Search GEO for disease gene expression data for Intestinal Obstruction.

Pathways for Intestinal Obstruction

Pathways related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 13.02 SGO1 RET NRTN MTOR GDNF FLNA
2 11.95 KRT7 KRT20 FLNA ACTG2
3
Show member pathways
10.69 RET NRTN GDNF

GO Terms for Intestinal Obstruction

Biological processes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane hyperpolarization GO:0060081 9.73 SLC26A3 CFTR
2 positive regulation of prostaglandin-endoperoxide synthase activity GO:0060585 9.71 NOD2 EDN3
3 intracellular pH elevation GO:0051454 9.67 SLC26A3 CFTR
4 vasoconstriction GO:0042310 9.63 CRP EDN3 EDNRB
5 vein smooth muscle contraction GO:0014826 9.62 EDNRB EDN3
6 posterior midgut development GO:0007497 9.56 RET EDNRB
7 enteric nervous system development GO:0048484 9.43 RET GDNF EDNRB
8 neural crest cell migration GO:0001755 9.32 RET NRTN GDNF EDNRB EDN3

Molecular functions related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glial cell-derived neurotrophic factor receptor binding GO:0030116 8.92 NRTN GDNF

Sources for Intestinal Obstruction

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....